In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nicaragua gets US help with new central laboratory:

This article was originally published in Clinica

Executive Summary

The US government is supplying the Nicaraguan health ministry with the laboratory equipment, reagents and other disposables needed to ensure it is able to monitor outbreaks of avian flu. The donation, which is being co-ordinated through the Central American state's US embassy, supports the establishment of the national diagnostic reference centre (CNDR). Announcing the initiative, health minister Maritza Cuan also welcomed an offer from the US Centers for Disease Control and Prevention (CDC), in Atlanta, as part of the WHO's network of reference testing centres, to perform the more specialised (viral sequencing) testing of samples, which Nicaragua will not be able to perform at the CNDR. Citing the views of US experts currently training staff for the centre, Dr Cuan said that the CNDR is set to significantly help improve the technical quality and speed of detection of diseases generally.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts